<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1704245169
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TEVETEN 600MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EPROSARTAN MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        76.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Mylan Laboratories SAS " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Mylan Laboratories SAS 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBOTT BIOLOGICALS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Teveten is used:<br />Eprosartan is indicated for the treatment of essential hypertension.<br />Teveten contains the active substance eprosartan.<br />- Eprosartan belongs to the group of medicines called angiotensin-II receptor antagonists.<br />Angiotensin-II is produced in your body and causes the blood vessels to narrow. This hinders the blood flow<br />through the vessels causing the blood pressure to rise. Eprosartan blocks this effect, so that the blood vessels relax<br />and the blood pressure falls.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>if you are allergic to any of the ingredients in this medicine. You can find these ingredients in section 6.<br />&bull; if you have severe liver function disorder.<br />&bull; if you have certain severe problems with your kidneys (poor blood flow because of bilateral narrowing of the renal<br />vessels or severe narrowing when only one kidney is working).<br />&bull; if you have diabetes or kidney function disorder and you are being treated with a blood pressure-lowering<br />medicine that contains aliskiren.<br />&bull; if you are more than 3 months pregnant (it is also better not to take this medicine at the start of pregnancy -<br />see also &ldquo;pregnancy&rdquo;).<br />If you are unsure whether any of the above-mentioned situations applies to you, please contact your doctor or<br />pharmacist before you take Teveten.</p><p>Warning and Precautions<br />Please contact your doctor or pharmacist before you take this medicine:</p><p>if you have other liver problems;<br />&bull; if you have other kidney problems, have undergone a kidney transplant or need haemodialysis. Your doctor<br />will assess your kidney function before and during treatment with Teveten;<br />&bull; if you are taking any of the following medicines to treat high blood pressure:<br />- an ACE inhibitor (e.g. enalapril, lisinopril, ramipril), particularly if you have diabetes-related kidney<br />problems.<br />- aliskiren.<br />Your doctor might carry out a regular check on your kidney function, blood pressure and the number of<br />electrolytes (e.g. potassium) in your blood. See also the information in the section &lsquo;Do not take this medicine&rsquo;.<br />&bull; if you have heart problems such as heart failure, a restriction of your blood vessels or palpitations or a<br />problem with your heart muscle;<br />&bull; if you suffer from a disorder that affects your adrenal glands (hyperaldosteronism);<br />&bull; if you know that the potassium levels in your blood have risen;<br />&bull; if you have fluid volume depletion, have low salt levels because you are following a salt- restricted diet, are taking<br />water tablets, have diarrhoea or are vomiting. These disorders must have cleared up completely before you start<br />taking eprosartan.</p><p>Tell your doctor if you think you are pregnant or want to become pregnant. Taking this medicine is not<br />recommended during early pregnancy. If you are more than 3 months pregnant, the medicine should not be taken,<br />because it may have serious adverse effects on the baby if you use it during this period (see also &ldquo;pregnancy&rdquo;).<br />Your doctor might want to see you more frequently and carry out additional tests, if any of the above-mentioned<br />situations applies to you.<br />In negroid patients, Teveten may be less effective in lowering blood pressure.</p><p>Other medicines and Teveten<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your doctor may adjust the dose and/or take other precautionary measures:<br />- if you are taking an ACE inhibitor or aliskiren (see also the information in the sections &lsquo;Do not take this<br />medicine&rsquo; and &lsquo;When should you be extra careful with this medicine?&rsquo;).<br />Make sure you tell your doctor if you are taking any of the following medicines:<br />&bull; other blood pressure-lowering medicines;<br />&bull; potassium supplements, potassium-sparing medicines or salt substitutes containing potassium (substances that<br />increase the amount of potassium in your blood);<br />&bull; heparin (a medicine for thinning your blood);<br />&bull; water tablets (diuretics);<br />&bull; lithium (to treat a form of depression);<br />&bull; painkillers with anti-inflammatory and antifebrile action (NSAIDs, such as ibuprofen).</p><p>If you are unsure whether any of the above applies to you, please contact your doctor or pharmacist before you<br />take Teveten.</p><p>This medicine with food and drink<br />&bull; You may take these tablets with or without food.<br />&bull; If you are following a low-salt diet, tell your doctor before you start taking Teveten. If you do not get enough<br />salt, your blood volume or the salt content in your blood can be reduced.</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor<br />or pharmacist for advice before taking this medicine.</p><p>Pregnancy<br />Tell your doctor if you think you are pregnant or want to become pregnant. Usually your doctor will advise you<br />to stop taking this medicine before you get pregnant or as soon as you know that you are pregnant and will<br />prescribe another medicine in its place. This medicine is not recommended for use during early pregnancy.<br />The medicine should not be used if you are more than 3 months pregnant, because it can have serious adverse<br />effects on the baby if you use it in this period.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or want to begin breast-feeding. This medicine is not recommended<br />for breast-feeding mothers. Your doctor can choose another treatment for you if you want to breast-feed,<br />especially if your baby is new-born or preterm.<br />Driving and usingmachines<br />Treatment of high blood pressure may cause dizziness or fatigue. So take care when driving and using machines.<br />Important information about a few ingredients of Teveten<br />Teveten tablets contain lactose. If your doctor has told you that you do not tolerate certain sugars, contact your<br />doctor before you take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />How should I take Teveten?<br />&bull; Always follow your doctor&rsquo;s instructions.<br />&bull; Take with sufficient water. Before, during or after meals. Choose a fixed time. This gives a regular effect and<br />prevents you forgetting.<br />&bull; Do not crush or chew the tablets.<br />&bull; The length of treatment differs for everyone.<br />&bull; After 2-3 weeks, the blood pressure-lowering effect is maximum.</p><p>Use in adults<br />The recommended dose is 600 mg once daily.<br />In case of moderate kidney function disorders, the dose is 600 mg once daily.</p><p>Use in children and adolescents<br />Teveten should not be given to children and adolescents under 18 years of age.<br />If you take more Teveten than you should<br />If you have taken more Teveten than you should or if someone has accidently taken some tablets, contact your<br />doctor immediately. Remember to take the packaging and the remaining tablets with you. If you have taken too<br />much Teveten, you may<br />&bull; feel dizzy or faint because your blood pressure has gone down too much;<br />&bull; feel nauseous;<br />&bull; feel drowsy.<br />If you forget to take this medicine<br />Take the dose as soon as you remember, unless it is almost time for the next dose. Do not take two doses</p><p>within 12 hours of each other and do not take a double dose to make up for a forgotten dose. Contact your doctor<br />if you have forgotten several doses.<br />If you stop taking this medicine<br />Your blood pressure might rise. Contact your doctor first before you stop taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everyone gets them.<br />Stop taking Teveten if any of the side effects listed below occur and inform your doctor immediately or go<br />to the accident and emergency department of the nearest hospital. You might need medical treatment if<br />you have the following symptoms:<br />&bull; itching swollen skin, skin rash;<br />&bull; shortness of breath or wheezing;<br />&bull; swelling of the face, lips, tongue and/or throat.<br />These may be the symptoms of a serious allergic reaction that might be life-threatening.<br />When using Teveten the following side effects may occur:</p><p>Very common (in more than 1 in 10 patients)<br />&bull; headache</p><p>Common (in more than 1 in 100, but in fewer than 1 in 10 patients)<br />&bull; raised level of some fats in the blood, called triglycerides (hypertriglyceridaemia)<br />&bull; dizziness<br />&bull; fatigue<br />&bull; depression<br />&bull; palpitations (fast heartbeat)<br />&bull; chest pain<br />&bull; inflammation of the nasal mucous membrane, characterised by a blocked nose, sneezing and nasal discharge<br />(rhinitis)<br />&bull; inflammation of the throat (pharyngitis)<br />&bull; shortness of breath<br />&bull; upper respiratory tract infection<br />&bull; cough<br />&bull; paranasal sinus inflammation (sinusitis)<br />&bull; inflammation of the airways, characterised by coughing and production of mucous (bronchitis)<br />&bull; non-specific gastrointestinal symptoms including nausea, diarrhoea and vomiting<br />&bull; abdominal pain<br />&bull; disturbed digestion with a full feeling or pain in the stomach area, belching, nausea, vomiting and heartburn<br />(dyspepsia)<br />&bull; allergic skin reactions including skin rash and itching (pruritus)<br />&bull; joint pain (arthralgia)<br />&bull; muscle pain (myalgia)<br />&bull; back pain<br />&bull; urinary tract infection<br />&bull; weakness (asthenia)<br />&bull; viral infection</p><p>&bull; injury<br />&bull; pain<br />&bull; oedema</p><p>Uncommon (in more than 1 in 1,000, but in fewer than 1 in 100 patients)<br />&bull; hypersensitivity<br />&bull; increased potassium level in the blood, sometimes with symptoms of muscle cramps, diarrhoea, nausea,<br />dizziness and/or headache (hyperkalaemia)<br />&bull; reduced blood pressure (hypotension), including fall in blood pressure due for example to standing up quickly<br />from a sitting or lying position, sometimes expressed as dizziness (orthostatic hypotension)<br />&bull; sudden fluid accumulation in the skin and mucous membranes (e.g. throat or tongue), respiratory problems<br />and/or itching and rash, often as an allergic reaction (angioedema)</p><p>Rare (in more than 1 in 10,000, but in fewer than 1 in 1,000 patients)<br />&bull; reduced level of a protein that transports oxygen and CO2 (haemoglobin) in your blood<br />&bull; increased level of a decomposition product of protein metabolism (urea) in your blood</p><p>Very rare (in more than 1 in 100,000, but in fewer than 1 in 10,000 patients)<br />&bull; abnormal liver function</p><p>Frequency unknown<br />&bull; swelling of the face<br />&bull; reduced kidney function, including kidney failure (e.g. narrowing of the arteries in the kidney) in at-risk<br />patients<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in<br />this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store above 25 &deg;C.<br />Store in the original packaging.<br />Shelf life: 3 years<br />Do not use this medicine after the expiry date which is stated on the carton after &ldquo;do not use after&rdquo; or &ldquo;exp&rdquo;. The<br />expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: eprosartan in the form of eprosartan mesylate.<br />Each tablet contains 600 mg eprosartan (Teveten 600).<br />The other ingredients in this medicine are:<br />&bull; Tablet core of Teveten 600 mg: lactose monohydrate, microcrystalline cellulose, pregelatinised starch,<br />crospovidone magnesium stearate and purified water<br />&bull; Tablet coating of Teveten 600 mg: hypromellose (E464), titanium dioxide (E171), macrogol 400 and<br />polysorbate 80 (E433).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Teveten 600, film-coated tablets:
White, capsule-shaped, marked 5046 on one side. Blister strip of 14 tablets, 14, 28 or 56 tablets per carton
The blisters are made of opaque PVC/PVDC/Al or PVC/PCTFE/Al
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />Abbott Healthcare Products B.V.,<br />The Netherland<br />Manufacturer<br />Mylan Laboratories SAS<br />Ch&acirc;illon-sur-Chalaronne, France<br />Packaged by:<br />AJA Pharmaceutical Industries Company Ltd. (AJA Pharma)<br />Hail 55414 , Hail Industry City MODON<br />Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in December 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يستخدم تيفيتين:</p><p>- يستخدم الإبروسارتان لمعالجة فرط ضغط الدم الأساسيز</p><p dir="RTL">یحتوي تیفیتین على مادة فعالة تسمى إبروسارتان میسیلات . واللذي ینتمي إلى مجموعة من الأدویة تسمى مثبطات مستقبلات أنجیوتنسین-ӀӀ . یعمل جسمك على إنتاج أنجیوتنسین-ӀӀ والذي یسبب ضیق الأوعیة الدمویة . وھذا یعیق تدفق الدم خلال الأوعیة الدمویة مما یؤدي إلى ارتفاع ضغط الدم .</p><p>یعمل إبروسارتان كمضاد لھذا التأثیر ،&nbsp; مما یؤدي إلى استرخاء الأوعیة الدمویة وانخفاض ضغط الدم .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال تیفیتین:</strong></p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الحساسیة (حساسیة) لأي من المكونات في ھذا الدواء . (المدرجة في القسم 6).</p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك اضطراب شدید في وظائف الكبد .</p><p dir="RTL">x إذا كنت تعاني من مشاكل حادة بالكلیتین (ضعف تدفق الدم بسبب تضییق الأوعیة الدمویة الكلویة أو تضییق شدید في حالة وجود كلیة واحدة فقط) .</p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بداء السكري أو اضطراب وظائف الكلى وكنت تعالج بالادویة التي تعمل على خفض ضغط الدم والتي تحتوي على ألیسكیرن</p><p>.</p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملا أكثر من 3 أشھر (من الأفضل أیضا عدم تناول ھذا الدواء في بدایة الحمل - انظر أیضا &laquo;الحمل&raquo;) .</p><p dir="RTL">یجب عدم تناول ھذا الدواء إذا كان أي مما سبق ینطبق علیك . إذا لم تكن متأكدا ، تحدث مع طبیبك أو الصیدلي قبل تناول تیفیتین .</p><p dir="RTL"><strong>التحذیرات والاحتیاطات: </strong></p><p dir="RTL">تحدث إلى طبیبك أو إلى الصیدلي قبل تناول تیفیتین .</p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك مشاكل أخرى في الكبد .</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لدیك مشاكل أخرى في الكلى ، خض عت لعملیة زرع الكلى أو تحتاج إلى غس یل الكلى . س یقوم طبیبك بتقییم وظائف الكلى قبل وأثناء العلاج بتناول تیفیتن .</p><p dir="RTL">x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي من الأدویة التالیة لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزیم المحول للأنجیوتنسین (على سبیل المثال إنالابریل ، لیسینوبریل ، رامیبریل) ، خاصة إذا كان لدیك مشاكل في الكلى ذات الصلة بالسكري .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألیسكیرین .</p><p dir="RTL">قد یقوم طبیبك بإجراء فحص منتظم على وظائف الكلى وضغط الدم ونسبة النواقل الكھربیة (مثل البوتاسیوم) في الدم . انظر أیضا المعلومات الواردة في قسم &quot;لا تأخذ ھذا الدواء&quot;.</p><p dir="RTL">إذا كان لدیك مشاكل في القلب مثل قصور القلب ، وإعاقات بالأوعیة الدمویة أو الخفقان أو مشكلة مع عضلة القلب. 􀁸<br />إذا كنت تعاني من اضطراب یؤثر على الغدد الكظریة (فرط الدوستیرونیة) . 􀁸<br />إذا كنت تعرف أن مستویات البوتاسیوم في الدم قد ارتفعت . 􀁸<br />إذا كنت تعاني من نضوب حجم السوائل ، فإن مستویات الملح ستكون منخفضة بسبب اتباع نظام غذائي مقید بالملح ، أو تناول أقراص مدرة 􀁸<br />للماء ، أو إسھال ، أو تقیؤ . یجب أن یتم التخلص تماما من ھذه الاضطرابات قبل البدء في تناول إبروسارتان .</p><p dir="RTL">أخبر طبیبك إذا كنت تعتقد أنك حامل أو تریدین أن تصبح حاملا . لا ینصح بتناول ھذا الدواء في بدایة الحمل . إذا كنت حاملا أكثر من 3 أشھر ،</p><p dir="RTL">فلا ینبغي تناول الدواء ، لأنھ قد یكون لھ آثار ضارة وخطیرة على الطفل (انظر أیضا&nbsp;.&nbsp;&raquo; الحمل &laquo;)</p><p dir="RTL">قد یرید طبیبك رؤیتك بشکل متکرر وإجراء اختبارات إضافیة ، إذا کان أي من الحالات المذکورة أعلاه تنطبق علیك .</p><p dir="RTL">في حالة مرضى النعاس ، قد یكون تیفیتن أقل فعالیة في خفض ضغط الدم .<br />تناول أدویة أخرى مع تیفیتین:<br />أخبر طبیبك أو الصیدلي أو الممرضة إذا كنت تناولت ، أو قد تتناول مؤخرا أي أدویة أخرى .</p><p dir="RTL">قد یقوم طبیبك بتعدیل الجرعة و / أو اتخاذ تدابیر احترازیة أخرى :<br />- إذا كنت تتناول مثبطات الإنزیم المحول للأنجیوتنسین أو ألیسكیرن (انظر أیضا المعلومات الواردة في أقسام &#39;لا تقم بتناول ھذا الدواء&#39;<br />و &#39;التحذیرات والإحتیاطات&#39;).</p><p dir="RTL">تأكد من إخبار الطبیب إذا كنت تتناول أي من الأدویة التالیة:</p><ul dir="rtl"><li>أدویة أخرى لخفض ضغط الدم .</li><li>مكملات البوتاسیوم ، أو الأدویة التي تحتوي على البوتاسیوم أو بدائل الملح التي تحتوي على البوتاسیوم (المواد التي تزید من كمیة البوتاسیوم&nbsp;<br />في الدم) .</li><li>الھیبارین (ھو دواء مضاد لتخثر الدم) .</li><li>أقراص المیاه (مدرات البول) .</li><li>اللیثیوم (لعلاج شكل من أشكال الاكتئاب) .</li><li>المسكنات التي تعمل كمضاد للالتھابات ومضادات الفیروسات (مضادات الالتھاب غیر الستیرویدیة ، مثل ایبوبروفین) .</li><li>إذا كانت أي من الحالات السابقة تنطبق علیك (أو إذا لم تكن متأكدا) ، تحدث مع طبیبك أو الصیدلي قبل تناول تیفیتین .</li></ul><p>تناول تیفیتین مع الطعام والشراب:</p><ul><li>یمكن تناول تیفیتین مع أو بدون طعام .&nbsp;</li><li>إذا كنت تتبع نظام غذائي منخفض الملح ، أخبر طبیبك قبل البدء في تناول تیفیتن. إذا لم تحصل على&nbsp;كمیة كافیة من الملح ، قد یقل حجم الدم&nbsp;أو محتوى الملح في الدم .</li></ul><p>الحمل والرضاعة الطبیعیة والخصوبة:</p><p>إذا كنت حاملا أو مرضعة,&nbsp;تعتقد أنك قد تكون حاملا أو تخططین للرضاعة الطبيعية,&nbsp;اطلب من طبیبك أو الصيدلي الحصول على المشورة قبل&nbsp;تناول ھذا الدواء .</p><p>الحمل:</p><p>أخبر طبیبك إذا كنت تعتقد أنك حامل أو ترید أن تصبحين&nbsp;حاملا . عادة ما ینصحك&nbsp;طبیبك بالتوقف عن تناول ھذا الدواء قبل الحمل أو بمجرد أن تعرفین أنك حامل وس وف ینص حك طبیبك بتناول دواء آخر بدلا من تیفیتین . لا ینصح&nbsp;باستخدام ھذا الدواء أثناء المراحل الأولى من الحمل .&nbsp; یجب عدم استخدام الدواء إذا كنت حاملا أكثر من 3 أشھر ، لأنھ یمكن أن یكون لھ آثار سلبیة خطیرة على الطفل إذا تم استخدامھ في ھذه الفترة .</p><p>الرضاعة الطبیعیة:</p><p>أخبر طبیبك إذا كنت ترضعین أو ترید أن تبدأي في الرضاعة الطبیعیة . لا ینصح بھذا الدواء للأمھات المرضعات . یمكن لطبیبك اختیار علاج آخر&nbsp;&nbsp;لك إذا كنت ترغبین في الرضاعة الطبیعیة ، خاصة إذا كان طفلك حدیث الولادة أو المبتسر .</p><p>القیادة واستخدام الآلات:</p><p>علاج ارتفاع ضغط الدم قد یسبب الدوخة أو التعب . لذا یجب توخي الحذر عند القیادة واستخدام الآلات .</p><p>معلومات ھامة عن بعض المكونات:</p><p>أقراص تیفیتن تحتوي على اللاكتوز . إذا أخبرك طبیبك أن لدیك مشاكل مع بعض السكریات ، اتصل بطبیبك قبل تناول ھذا الدواء .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدواء كما وصف الطبیب لك ، استشر طبیبك أو الصیدلي إن لم تكن متأكداً .</p><p>طریقة تناول ھذا الدواء</p><ul><li>اتبع دائما تعلیمات طبیبك .</li><li>تناول كمیة كافیة من الماء . ویتم التناول قبل أو أثناء أو بعد الوجبات . وینبغي اختیار وقت محدد . فھذا یعطي تأثیر منتظم ویمنع نسيان&nbsp;تناول الجرعة .</li><li>لا تقم بسحق أو مضغ الأقراص .</li><li>تختلف طول فترة العلاج من شخص لآخر .</li><li>أقصى تأثیر لخفض ضغط الدم بعد 2-3 أسابيع</li></ul><p>الاستخدام للبالغین</p><p>الجرعة الموصى بھا ھي 600 ملغم مرة واحدة یومیا .</p><p>في حالة اضطرابات وظائف الكلى الطبیعیة ، الجرعة ھي 600 ملغم مرة واحدة یومیا .</p><p>استخدام للأطفال والمراھقین</p><p>لا ینبغي إستخدام تیفیتن للأطفال والمراھقین الذین تقل أعمارھم عن 18 سنة .</p><p>إذا تناولت جرعة زائدة من تیفیتین:</p><p>إذا تناولت تیفیتین أكثر مما ینبغي ، أو إذا كان شخص ما تناول عن طریق الخطأ بعض الأقراص ، اتصل بطبیبك على الفور . تذكر أن تأخذ العبوة&nbsp;والأقراص المتبقیة معك . إذا تناولت تیفیتین أكثر مما ینبغي قد تعاني مما یلي:</p><ul><li>الشعور بالدوار أو الضعف لأن ضغط الدم قد انخفض كثیرا</li><li>الشعور بالضوضاء .</li><li>الشعور بالنعاس .</li></ul><p>إذا نسیت تناول تیفیتین:</p><p>إذا نسیت أن تتناول جرعة من الأقراص تناول الجرعة بمجرد أن تتذكرھا ، ما لم یكن وقت الجرعة التالیة قد اقترب . لا تأخذ جرعتین في غضون<br />12 ساعة من بعضھا البعض ، ولا تتناول جرعة مضاعفة للتعویض الجرعة المنسیة . اتصل بطبیبك إذا كنت قد نسیت تناول العدید من الجرعات .</p><p>التوقفت عن تناول تیفیتین:</p><p>قد یرتفع ضغط الدم . اتصل بطبیبك أولا قبل التوقف عن تناول ھذا الدواء .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة ، یمكن أن یتسبب ھذا الدواء في آثار جانبیة ، على الرغم من أنھا لا تؤثر في الجمیع . الآثار الجانبیة التالیة قد تحدث مع تناول&nbsp;ھذا الدواء:</p><p>یجب التوقف عن تناول تیفیتین واستشر الطبیب أو اذھب إلى قسم الحوادث والطوارئ في أقرب مستشفى على الفور إذا عانیت من الأعراض&nbsp;التالیة ، فقد تحتاج إلى علاج طبي عاجل إذا كانت لدیك:</p><ul><li>الحكة تورم الجلد ، الطفح الجلدي .</li><li>ضیق في التنفس أو الصفیر .</li><li>تورم الوجھ والشفتین واللسان و / أو الحلق</li></ul><p>قد تكون ھذه أعراض رد فعل تحسسي خطیر وقد یكون مھددا للحیاة .</p><p>عند استخدام تیفیتن قد تحدث الآثار الجانبیة التالیة:</p><p>شائعة جدا (قد تصیب أكثر من شخص من أصل 10 شخص)</p><ul><li>صداع الراس</li></ul><p>شائعة (قد تصیب ما یصل إلى شخص من أصل 10 شخص أو في أكثر من شخصمن أصل 100 شخص) .</p><ul><li dir="rtl">إرتفاع مستوى بعض الدھون في الدم ، التي تسمى الدھون الثلاثیة (ارتفاع دھون الدم) .</li><li dir="rtl">الدوخة&nbsp;</li><li dir="rtl">إعیاء&nbsp;</li><li dir="rtl">كآبة&nbsp;</li><li dir="rtl">خفقان (ضربات القلب السریعة)&nbsp;</li><li dir="rtl">ألم في الصدر&nbsp;</li><li dir="rtl">التھاب الغشاء المخاطي للأنف ، وتتمیز بإنسداد في الأنف ، والعطس والإفرازات الأنفیة (التھاب الأنف)&nbsp;</li><li dir="rtl">التھاب الحلق (البلعوم)&nbsp;</li><li dir="rtl">ضیق في التنفس&nbsp;</li><li dir="rtl">عدوى الجھاز التنفسي العلوي&nbsp;</li><li dir="rtl">سعال&nbsp;</li><li dir="rtl">التھاب الجیوب الأنفیة&nbsp;</li><li dir="rtl">التھاب الشعب الھوائیة ، وتتمیز بالسعال والإفرازات المخاطیة (التھاب الشعب الھوائیة)&nbsp;</li><li dir="rtl">أعراض معدیة غیر محددة بما في ذلك الغثیان والإسھال والقيء&nbsp;</li><li dir="rtl">وجع بالبطن&nbsp;</li><li dir="rtl">اضطراب الھضم مع الشعور الكامل أو ألم في منطقة المعدة ، والتجشؤ ، والغثیان ، والتقیؤ وحرقة (عسر الھضم)&nbsp;</li><li dir="rtl">ردود فعل الجلد التحسسي بما في ذلك الطفح الجلدي والحكة</li><li>آلام المفاصل (ألم مفصلي)&nbsp;</li><li>آلام في العضلات (ألم عضلي)&nbsp;</li><li>ألم في الظھر&nbsp;</li><li>التھاب المسالك البولیة&nbsp;</li><li>الضعف (الوھن)&nbsp;</li><li>عدوى فیروسیة&nbsp;</li><li>إصابھ&nbsp;</li><li>الم&nbsp;</li><li>استسقاء</li></ul><p>غیر شائعة (قد تصیب ما یصل إلى شخص من أصل 100 شخص أو في أكثر من شخص من أصل 1000 شخص)</p><ul><li>فرط الحساسیة</li><li>زیادة مستوى البوتاسیوم في الدم ، وأحیانا مع أعراض تشنجات العضلات ، والإسھال ، والغثیان ، والدوخة و / أو الصداع (فرط بوتاسیوم الدم) .</li><li>انخفاض ضغط الدم ، بما في ذلك انخفاض ضغط الدم نتیجة الوقوف بسرعة من موضع الجلوس أو الإستلقاء ، والذي یعبر عنھ أحیانا بالدوخة&nbsp;(انخفاض ضغط الدم الانتصابي) .</li><li>تراكم السوائل المفاجئ في الجلد والأغشیة المخاطیة (على سبیل المثال الحلق أو اللسان) ، ومشاكل في الجھاز التنفسي و / أو الحكة والطفح&nbsp;الجلدي ، وغالبا ما یكون رد فعل تحسسي (وذمة وعائیة)</li></ul><p>نادر (قد تصیب ما یصل إلى شخص من أصل 1000 شخص أو في أكثر من شخص من أصل 10000 شخص):</p><ul><li>انخفاض مستوى البروتین (الھیموجلوبین) الذي ینقل الأكسجین وثاني أكسید الكربون في الدم .</li><li>زیادة مستوى منتج التحلل من أیض البروتین (الیوریا) في الدم .</li></ul><p>نادرة جدا (قد تصیب ما یصل إلى شخص من أصل 10000 شخص أو في أكثر من شخص من أصل 100000 شخص)</p><ul><li>وظائف الكبد غیر طبیعیة</li></ul><p>أعراض جانبیة غیر معلوم معدلاتھا</p><ul><li>تورم في الوجھ .</li><li>انخفاض وظائف الكلى ، بما في ذلك الفشل الكلوي (على سبیل المثال تضییق الشرایین في الكلى) في المرضى المعرضین للخطر</li></ul><p dir="RTL">إذا زادت حدة أي من ھذه الأعراض الجانبیة ، أو لاحظت ظھور أعراض جانبیة غیر ما تم ذكره في ھذه النشرة ، یرجى إبلاغ الطبیب المعالج أو الصيدلي . وھذا یشمل أي آثار جانبیة محتملة غیر مدرجة في ھذه النشرة . بالإبلاغ عن الآثار الجانبیة یمكنك المساعدة في توفیر مزید من المعلومات حول أمان ھذا الدواء .&nbsp;</p><p>للإبلاغ عن الأعراض الجانبیة<br />- المركز الوطني للتیقظ والسلامة الدوائیة<br />+966-1-205- فاكس 7662 o<br />2340-2334-2354-2353-2356- 2038222 ، تحویلة: 2317 -11- الاتصال على المركز الوطني للتیقظ والسلامة الدوائیة + 966 o<br />الھاتف المجاني: 8002490000 o<br />npc.drug@sfda.gov.sa : البرید الإلكتروني o<br />www.sfda.gov.sa/npc : الموقع الإلكتروني o</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>یحفظ بعیدا عن متناول أیدي الأطفال أو على مرأى منھم .</li><li>لا یخزن في درجة حرارة أعلى من 25 درجة مئویة</li><li>یحفظ داخل العبوة الأصلیة</li><li>فترة الصلاحية: 3 سنوات&nbsp;</li><li>لا تستخدم تیفیتین بعد انتھاء تاریخ الصلاحیة المذكور على العبوة الخارجیة . تاریخ انتھاء الصلاحیة یشیر إلى الیوم الأخیر من ذلك الشھر</li><li><p dir="RTL">لا ینبغي أن یتم التخلص من الأدویة في میاه الص رف الص حي أو عن طریق النفایات المنزلیة . اس أل الص یدلي عن كیفیة التخلص من الأدویة التي لم تعد مطلوبة . ھذه التدابیر تساعد في الحفاظ على البیئة .</p></li><li><p dir="RTL">&nbsp;</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما تحویھ علبة تیفیتین:</p><ul><li>المادة الفعالة ھي إبروسارتان . على ھیئة إبروسارتان میسیلات .</li><li>يحتوي كل قرص من تيفيتين 600 ملغم على 600 ملغم ايبروسارتان</li></ul><p>الصواغات الأخرى:</p><ul><li>الصواغات الأساسیة في أقراص تیفیتن 600 ملغم : مونوھیدرات اللاكتوز ، السلیلوز الجریزوفولفین ، نشا سابق التجلتن&nbsp;، كروسكارملوز الصودیوم وستیرات المغنیسیوم .</li><li>طبقة الكسوة الخارجیة في أقراص تیفیتن 400 ملغم: ھایبرومیلوز (E464) ، وثاني أكسید التیتانیوم (E171 ،)&nbsp; ماكروجول 400 ، بولیسوربات 80 (E433)&nbsp;</li></ul><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ماهوا شكل تيفيتين ومحتويات العلبة؟</p><p>تیفیتن&nbsp; 600 ، أقراص مغطاة بطبقة رقیقة عبارة عن أقراص على ش كل كبس ولة ، ذات اللون الأبیض محفور علیھا علامة 5046 على جانب واحد . یحتوي الشریط على 14 قرص وتحتوي العلبة على 14 أو&nbsp; 28 قرص .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب حق التسويق:</p><p>أبوت هيلث كير برودكتس بيز في, هولاندا</p><p>المصنع:</p><p>مايلان لابوراتوريز اس اي اس</p><p>01400 شاتيلون سور شارلون فرنسا&nbsp;</p><p>تم التغليف في:</p><p>&nbsp;شركة اجا للصناعات الدوائیة المحدودة (اجا فارما)</p><p>حائل ٥٥٤۱٤ ، المدینة الصناعیة &ndash; حائل</p><p>المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Teveten® 600, film-coated tablets 600 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Teveten 600 contains 735.8 mg of eprosartan mesylate equivalent to
600 mg of eprosartan.
Excipient with known effect:
Each film-coated Teveten 600 contains 43.3 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Teveten 600 are white capsule-shaped film-coated tablets marked 5046 on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Essential hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose is 600 mg once daily.<br />In most patients, the maximum blood pressure-lowering effect is reached 2 to 3 weeks after<br />starting the therapy.<br />Eprosartan can be used as a monotherapy or in combination with other antihypertensives (see<br />sections 4.3, 4.4, 4.5 and 5.1). Thiazide diuretics in particular, such as hydrochlorothiazide or<br />calcium channel-blocking agents, have been found to have an additive effect on eprosartan.<br />Eprosartan can be taken with or without food.<br />Elderly patients<br />In elderly patients, the dosage does not have to be adjusted.<br />Dosage in hepatically impaired patients<br />Adjustment of the dose is not required in patients with mild to moderate hepatic impairment.<br />Eprosartan is contraindicated in patients with severe hepatic impairment (see section 4.3.)<br />Dosage in renally impaired patients<br />In patients with moderate to severe renal impairment (creatinine clearance &lt; 60 ml/min.), the<br />daily dosage should not exceed 600 mg.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients indicated in section 6.1.
• Second and third trimester of pregnancy (see sections 4.4 and 4.6).
• Severe hepatic impairment.
• Haemodynamically significant bilateral renovascular disease or severe stenosis in a single
functioning kidney.
• The concomitant use of Teveten with aliskiren-containing medicinal products is
contraindicated in patients with diabetes mellitus or renal insufficiency (GFR < 60
ml/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepatic impairment<br />Caution is advised if eprosartan is used in patients with mild to moderate hepatic impairment,<br />because there is only limited experience with this patient group.<br />Renal impairment<br />In patients with moderate to severe renal impairment (creatinine clearance &lt; 60 ml/min.), the<br />daily dosage should not exceed 600 mg. Caution is advised when used by patients with<br />creatinine clearance &lt; 30 ml/min and by patients undergoing dialysis.<br />Eprosartan is contraindicated in patients with severe unilateral or bilateral renal artery stenosis<br />(see section 4.3). In the case of impaired renal function, e.g. as a result of renal artery stenosis,<br />acute deterioration of renal function should be taken into account. In such patients, it is advisable<br />to monitor renal function during the treatment.<br />Caution is advised in patients undergoing haemodialysis. There is no experience with<br />administration of eprosartan in patients who have recently had a kidney transplant.</p><p>Patients at risk of renal impairment<br />Some patients whose renal function is dependent on the constant inherent activity of the reninangiotensin-<br />aldosterone system (e.g. patients with severe cardiac failure [NYHA classification:<br />class IV], bilateral renal artery stenosis or renal artery stenosis in a single functioning kidney), run<br />the risk of developing oliguria and/or progressive azotaemia and in rare cases acute kidney<br />failure during treatment with an angiotensin-converting enzyme (ACE)-inhibitor. Patients who<br />are being treated concomitantly with a diuretic have a greater chance of acquiring these<br />symptoms. In patients who are sensitive to this, there is insufficient therapeutic experience with<br />angiotensin-II receptor blockers, such as eprosartan, to determine whether there is a comparable<br />risk of compromising renal function. If eprosartan is used in patients with impaired renal<br />function, before starting the treatment with eprosartan and also at intervals during the therapy,<br />renal function should be evaluated. If, during the therapy, worsening of renal function is noted,<br />the treatment with eprosartan should be reconsidered.</p><p>Based on experience with other drugs of this class and ACE inhibitors, the following general<br />precautions apply:</p><p>Hyperkalaemia</p><p>During treatment with other drugs that act on the renin-angiotensin-aldosterone system,<br />hyperkalaemia can occur. This applies in particular to patients with impaired renal function<br />and/or heart failure. In patients at risk, careful monitoring of serum potassium is recommended.</p><p>Based on experience with other drugs that act on the renin-angiotensin-aldosterone system,<br />concomitant use of potassium-sparing diuretics, potassium supplements, potassium-containing<br />salt substitutes or other drugs that can increase serum potassium (e.g. heparin) leads to<br />increased serum potassium. A combination of these drugs with eprosartan should therefore be<br />used with caution.</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />There is evidence that in case of concomitant use of ACE inhibitors, angiotensin II receptor<br />antagonists or aliskiren the risk of hypotension, hyperkalaemia and a reduced renal function<br />(including acute renal failure) increases. Dual blockade of RAAS by the combined use of ACE<br />inhibitors, angiotensin II receptor antagonists or aliskiren is therefore not recommended (see<br />sections 4.5 and 5.1).<br />If treatment with dual blockade is considered absolutely necessary, this may only be carried out<br />under specialist supervision and the renal function, electrolytes and blood pressure should be<br />checked regularly.<br />ACE inhibitors and angiotensin II receptor antagonists should not be taken simultaneously by<br />patients with diabetic nephropathy.</p><p>Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism should not be treated with eprosartan.</p><p>Hypotension<br />In patients with severe sodium and/or volume depletion (for example when high doses of<br />diuretics are administered), symptomatic hypotension can occur after starting eprosartan<br />therapy. Sodium and/or volume depletion should be corrected before commencing the<br />eprosartan treatment, or the set dose of diuretics should be reduced.<br />Coronary heart disease<br />There is limited experience in patients with coronary heart disease.<br />Aortic and mitral valve stenosis and hypertrophic cardiomyopathy<br />As applies to all vasodilators, eprosartan should be used with caution in patients with aortic and<br />mitral valve stenosis or hypertrophic cardiomyopathy.</p><p>Pregnancy<br />Therapy with angiotensin II receptor antagonists should not be initiated during pregnancy.<br />Patients who are planning pregnancy should be changed to an alternative antihypertensive<br />therapy with a known safety profile for use during pregnancy, unless continuation of the<br />treatment with angiotensin II receptor antagonists is considered necessary. If pregnancy is<br />diagnosed, the treatment with an angiotensin II receptor antagonist should be stopped<br />immediately and, if necessary, an alternative therapy should be started (see sections 4.3 and<br />4.6).<br />Other warnings and precautionary measures<br />As is seen with angiotensin-converting enzyme inhibitors, eprosartan and the other angiotensin<br />II receptor antagonists lower blood pressure in negroid people clearly less effectively than in<br />non-negroid people, possibly because of a higher prevalence of low renin in the negroid<br />hypertensive population.</p><p>Lactose</p><p>Patients with rare hereditary disorders, such as galactose intolerance, Lapp lactase deficiency or<br />glucose-galactose malabsorption, should not use this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on placebo-controlled clinical studies in which a significantly increased serum potassium<br />concentration was observed, and based on experience with the use of other medicinal products<br />that influence the renin-angiotensin-aldosterone system, concomitant use of potassium-sparing<br />diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that can<br />increase serum potassium levels (e.g. heparin) can lead to increased serum potassium.<br />The data from clinical studies show that dual blockade of the renin-angiotensin-aldosterone<br />system (RAAS) in case of the combined use of ACE inhibitors, angiotensin II receptor<br />antagonists and aliskiren, is connected with a higher frequency of undesirable effects such as<br />hypotension, hyperkalaemia and a reduced renal function (including acute renal failure)<br />compared with the use of a single medicinal product that works on the RAAS (see sections 4.3,<br />4.4 and 5.1).</p><p>The antihypertensive effect can be intensified by other antihypertensives.<br />Toxicity and reversible increases in serum lithium concentrations have been reported during<br />concomitant use of lithium-containing medicinal products and ACE inhibitors. The possibility<br />of a similar effect after using eprosartan cannot be excluded and careful monitoring of the<br />lithium serum concentrations is recommended during concomitant use.<br />In vitro studies have shown that eprosartan does not inhibit the cytochrome P450 enzymes<br />CYP1A, 2A6, 2C9/8, 2C19, 2D6, 2E and 3A.</p><p>As with ACE inhibitors, concomitant use of angiotensin II receptor antagonists with NSAIDs<br />(non-steroidal anti-inflammatory drugs [e.g. COX-2 inhibitors, acetylsalicylic acid (&gt;3 g/daily)<br />and non-selective NSAIDs]) may lead to an increased risk of renal function deterioration,<br />including possible acute renal failure and an increase in serum potassium, especially in patients<br />who already have impaired renal function. Caution is advised when administering this<br />combination, particularly in the elderly. Patients should be adequately hydrated and monitoring of<br />renal function should be considered both after commencement of the combination therapy and<br />periodically thereafter.<br />Concomitant use of losartan with the NSAID indomethacin has led to reduced effectiveness of the<br />angiotensin II receptor antagonist; a class effect cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of angiotensin II receptor antagonists is not recommended during the first trimester of<br />pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contraindicated<br />during the second and third trimester of pregnancy (see sections 4.3 and 4.4).<br />No clear conclusions can be drawn from the results of epidemiological investigation of the risk<br />of teratogenic effects as a consequence of exposure to angiotensin II receptor antagonists<br />during the first trimester of pregnancy; a slight increase in the risk can, however, not be<br />excluded. Although there are no controlled epidemiological data on the risk with angiotensin II<br />receptor antagonists, the risk may be comparable with this class of drugs. Patients who plan a<br />pregnancy should be changed to an alternative antihypertensive therapy with a known safety<br />profile for use during pregnancy, unless continuation of the treatment with an angiotensin II<br />receptor antagonist is considered necessary. If pregnancy is diagnosed, the treatment with</p><p>angiotensin II receptor antagonists should be stopped immediately and, if necessary, an<br />alternative therapy should be started.<br />It is known that exposure to angiotensin II receptor antagonists during the second and third<br />trimester can induce foetal toxicity (deteriorated renal function, oligohydramnios, skull<br />ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see<br />also section 5.3). If there has been exposure to angiotensin II receptor antagonists after the<br />second trimester of pregnancy, an ultrasound check of renal function and the skull is advised.<br />Neonates whose mothers have used angiotensin II receptor antagonists should be monitored<br />closely for hypotension (see also sections 4.3 and 4.4).</p><p>Lactation<br />Because no information is available on the use of Teveten during breastfeeding, Teveten is not<br />recommended and alternative treatments with a known safety profile are preferred for use during<br />breastfeeding, particularly when nursing a new-born or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of eprosartan on the ability to drive and use machines has not been investigated, but<br />based on the pharmacological properties an effect is unlikely. When driving and using<br />machines, it should be borne in mind that when treating hypertension dizziness or fatigue may<br />occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported undesirable effects in patients treated with eprosartan are<br />headache and non-specific gastrointestinal disorders, which occur in approximately 11% and<br />8%, respectively, of patients.<br />The following undesirable effects have been reported in clinical trials, in which patients were<br />treated with eprosartan (n = 2316).<br />The undesirable effects are reported per system/organ class and according to their frequency.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:91px">Organ system</td><td style="width:79px">Very<br />common<br />&ge;1/10</td><td style="width:68px">Common<br />&gt;1/100 -<br />&lt;1/10</td><td style="width:88px">Uncommon<br />&gt;1/1,000 -<br />&lt;1/100</td><td style="width:73px">Rare<br />&gt;1/10,000<br />- &lt;1/1,000</td><td style="width:100px">Very rare<br />&lt;1/10,000<br />including<br />isolated<br />reports</td><td style="width:100px">Unknown,<br />cannot be<br />estimated from<br />the available<br />data</td></tr><tr><td style="width:91px">Immune system<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">&nbsp;</td><td style="width:88px">Hypersensitivity*</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Metabolism and<br />nutrition<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Hypertriglyceridaemia</td><td style="width:88px">Hyperkalaemia</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Nervous system<br />disorders</td><td style="width:79px">Headache*</td><td style="width:68px">Dizziness*,<br />Fatigue,<br />Depression</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Cardiac disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Palpitations,<br />Chest pain</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Vascular<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">&nbsp;</td><td style="width:88px">Hypotension,<br />including&nbsp;orthostatic<br />hypotension</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Respiratory,<br />thoracic and<br />mediastinal<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Rhinitis,<br />Pharyngitis,<br />Dyspnoea,<br />Upper<br />respiratory<br />tract<br />infection,<br />Cough,<br />Sinusitis,<br />Bronchitis</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Gastrointestinal<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Non-specific<br />gastrointestinal<br />system<br />disorders<br />(e.g. nausea,<br />diarrhoea,<br />vomiting),<br />Abdominal<br />pain,<br />Dyspepsia</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Hepatobiliary<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">&nbsp;</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">Impaired<br />liver<br />function</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Skin and subcutaneous<br />tissue<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Allergic skin<br />reactions<br />(e.g. rash,<br />pruritus)</td><td style="width:88px">Angiooedema*</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">Facial swelling</td></tr><tr><td style="width:91px">Musculoskeletal<br />and connective<br />tissue disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Arthralgia,<br />Myalgia,<br />Backache</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Renal and urinary<br />disorders</td><td style="width:79px">&nbsp;</td><td style="width:68px">Urinary tract<br />infection</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">Impaired renal<br />function<br />including renal<br />failure in<br />patients at risk<br />(e.g. renal artery<br />stenosis)</td></tr><tr><td style="width:91px">General disorders<br />and<br />administration<br />site conditions</td><td style="width:79px">&nbsp;</td><td style="width:68px">Asthenia,<br />Viral<br />infection,<br />Injury, Pain,<br />Oedema</td><td style="width:88px">&nbsp;</td><td style="width:73px">&nbsp;</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr><tr><td style="width:91px">Investigations</td><td style="width:79px">&nbsp;</td><td style="width:68px">&nbsp;</td><td style="width:88px">&nbsp;</td><td style="width:73px">Reduced<br />haemoglobin<br />count,<br />Elevated<br />blood urea<br />nitrogen</td><td style="width:100px">&nbsp;</td><td style="width:100px">&nbsp;</td></tr></tbody></table><p>*Did not occur at a higher frequency than the placebo</p><p>The following undesirable effects were reported spontaneously during post-marketing use of<br />eprosartan, in addition to the undesirable effects reported during clinical studies. Frequencies<br />cannot be estimated from the available data (unknown).<br />Renal and urinary disorders<br />Impaired renal function, including renal failure in patients at risk (e.g. renal artery stenosis).</p><p>Reporting suspected adverse drug reactions<br />It is important to report any suspected adverse drug reactions after authorisation of the<br />medicinal product. In this way the relationship between the benefits and risks of the medicinal<br />product can be constantly monitored. Healthcare professionals are asked to report all suspected<br />adverse drug reactions.</p><p>To report any side effect(s):<br />-National Pharmacovigilance Center (NPC)<br />o Fax: +966-1-205-7662<br />oCall NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />oToll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available on overdose in humans. There were individual post-marketing reports,<br />where dosages of up to 12,000 mg were taken. Most patients have not reported any symptoms.<br />One person suffered circulatory collapse after taking 12,000 mg of eprosartan. This person<br />recovered completely. The most likely manifestation of overdose is hypotension. The patient<br />should then be placed in a lying position, after which salt and fluid can be administered. The<br />treatment should be symptomatic and supportive. Depending on the time that has elapsed since<br />ingestion, the treatment may consist of induced vomiting, gastric lavage and/or administration of<br />activated carbon.<br />Eprosartan cannot be removed through haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II (AT1) antagonists: ATC code: C09CA02.<br />Eprosartan is a potent, synthetic, orally active non-biphenyl tetrazole angiotensin II receptor<br />antagonist, which binds selectively to the AT1 receptor. Angiotensin II plays an important role<br />in the pathophysiology of hypertension. Angiotensin II binds to the AT1 receptor in many<br />tissues (e.g. smooth vascular musculature, adrenal glands, kidneys and heart) and activates<br />several important biological mechanisms, such as vasoconstriction, sodium retention and<br />release of aldosterone.<br />In healthy volunteers, eprosartan antagonised the effect of angiotensin II on blood pressure,<br />renal blood flow and the release of aldosterone. Whether eprosartan is now administered in a<br />single dose or in two half doses, it has a comparable effect on blood pressure in hypertensive</p><p>patients. This effect on blood pressure is maintained constant for a period of 24 hours. In<br />hypertensive patients, lowering of blood pressure did not cause any change in the heart rate.<br />In the MOSES study (morbidity and mortality after stroke, eprosartan compared with<br />nitrendipine for secondary prevention), 1,405 hypertensive patients with a history of<br />cerebrovascular events were treated with eprosartan or nitrendipine. In the eprosartan group,<br />78% of the patients received 600 mg once daily and 12% up to 800 mg daily; in the<br />nitrendipine group, 47% received 10 mg and 42% 20 mg daily (11% up to 40 mg) in a<br />prospective, randomised, open-label, blinded endpoint design. The defined primary endpoint<br />included mortality through all causes, cerebrovascular events (TIA, PRIND, stroke) and<br />cardiovascular events (unstable angina, myocardial infarction, heart failure, pulmonary<br />embolism and fatal cardiac dysrhythmia) including recurrent events. In both treatment arms, the<br />blood pressure objectives were achieved and maintained throughout the study. The primary<br />endpoint showed a significantly better result in the eprosartan group (21% risk reduction). The<br />numerical risk reduction was in the first analysis of the events 12% for the cerebrovascular<br />endpoints and 30% for the cardiovascular endpoints. These results were due in particular to a<br />reduction in the incidence of TIA/PRIND, unstable angina and heart failure. Overall mortality<br />was numerically in favour of nitrendipine; in the eprosartan group, 57 of the 681 patients died<br />versus 52 of 671 patients in the nitrendipine group (HR 1.07, 95% CI 0.73 - 1.56, p=0.725).<br />Fatal and non-fatal myocardial infarction occurred in 18 versus 20 patients and stroke in 36<br />versus 42 patients; numerically this is in favour of eprosartan. For the primary endpoint, the<br />effect of eprosartan seemed to be more pronounced in patients who were not given beta<br />blockers.</p><p>In hypertensive patients, eprosartan has no effect on fasting triglyceride, total cholesterol or<br />LDL cholesterol levels. In addition, eprosartan has no effect on fasting blood sugar levels.<br />Eprosartan has been studied in both mild to moderate hypertensive patients (sitting diastolic blood<br />pressure between 95 and 115 mmHg) and severe hypertensive patients (sitting diastolic blood<br />pressure between 115 and 125 mmHg).<br />Eprosartan&rsquo;s effect on mortality and cardiovascular morbidity is not currently known.<br />In normal adult males, eprosartan has been shown to increase mean effective renal plasma flow.<br />Eprosartan does not reduce glomerular filtration rate in healthy males, in hypertensive patients<br />or in patients with varying degrees of renal insufficiency. Eprosartan has a natriuretic effect on<br />normal subjects on a low-salt diet.<br />Eprosartan has no significant effect on the excretion of uric acid.</p><p>Eprosartan does not potentiate the effects of (ACE-mediated) bradykinin, e.g. cough.<br />In a study specifically aimed at comparing the incidence of cough in patients treated with<br />eprosartan or an ACE inhibitor, the incidence of a persistent dry cough was significantly lower<br />(p&lt;0,05) in the patients treated with eprosartan (1.5%) than in patients treated with an ACE<br />inhibitor (5.4%). In another study of the incidence of cough in patients who had earlier coughed<br />whilst taking an ACE inhibitor, the incidence of persistent dry cough was 2.6% in the<br />eprosartan group, 2.7% in the placebo group and 25.0% in the group treated with an ACE<br />inhibitor. The difference in the incidence of persistent dry cough between the eprosartan group<br />and the ACE inhibitor group was statistically significant (p&lt;0.01), whereas the difference<br />between the eprosartan group and the placebo group was not.</p><p>It emerged from three clinical studies (n=791) that the blood pressure-lowering effect of<br />eprosartan was at least as high as that of an ACE inhibitor.</p><p>In two big randomised controlled trials (ONTARGET &ndash; ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial and VA NEPHRON-D &ndash; The Veterans<br />Affairs Nephropathy in Diabetes) the use of the combination of an ACE inhibitor with an<br />angiotensin II receptor antagonist was investigated.</p><p>ONTARGET was a study in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus in combination with signs of target organ damage. VA<br />NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy. In<br />these studies no relevant positive effect on renal function and/or cardiovascular outcomes and<br />mortality was found, while an increased risk of hyperkalaemia, acute renal damage and/or<br />hypotension was seen compared with monotherapy. In view of their corresponding<br />pharmacodynamic properties these outcomes are also relevant for other ACE inhibitors and<br />angiotensin II receptor antagonists.<br />ACE inhibitors and angiotensin II receptor antagonists should therefore not be taken<br />concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease<br />Endpoints) was a study that was set up to investigate the advantage of adding aliskiren to the<br />standard treatment of an ACE inhibitor or an angiotensin II receptor antagonist in patients with<br />type 2 diabetes mellitus and chronic renal disease, cardiovascular disease or both. The study<br />was terminated prematurely because of an increased risk of negative outcomes.<br />Cardiovascular mortality and stroke both occurred numerically more frequently in the aliskiren<br />group than in the placebo group, while undesirable effects and major severe undesirable effects<br />(hyperkalaemia, hypotension and renal dysfunction) were reported more frequently in the<br />aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absolute bioavailability after a single 300-mg oral dose of eprosartan is approximately 13%,<br />due to limited oral absorption. The peak concentration of eprosartan (when fasting) is reached<br />after 1-2 hours. Between 100 and 200 mg, the plasma concentration is directly doseproportional,<br />but at doses of 400 and 800 mg this is less the case. The terminal elimination halflife<br />of eprosartan after oral administration is 5 to 9 hours.<br />Chronic use of eprosartan does not show any significant accumulation. Administration of<br />eprosartan with food delays absorption, with minor changes observed (&lt; 25%) in Cmax and<br />AUC, which are not, however, of clinical significance.</p><p>Plasma protein binding of eprosartan is high (approximately 98%) and constant in the whole<br />concentration range of the therapeutic doses. The extent of protein-binding is not influenced by<br />gender, age, hepatic dysfunction or a mild to moderate/severe renal impairment, but in a small<br />number of patients with severe renal impairment it is seen to decrease.<br />Eprosartan can be administered in combination with lipid-lowering drugs, such as lovastatin,<br />simvastatin, pravastatin, fenofibrate, gemfibrizole and niacin.<br />Following intravenous administration of [14C] eprosartan, about 61% of radioactivity is<br />recovered in the faeces and about 37% in the urine. Following oral administration of [14C]<br />eprosartan, about 90% of radioactivity is recovered in the faeces and about 7% in the urine.</p><p>Following oral and intravenous administration of [14C] eprosartan to human subjects, only<br />eprosartan is recovered in the plasma and the faeces. In the urine, approximately 20% of the&nbsp;radioactivity excreted consisted of an acyl glucuronide of eprosartan, whilst the remaining 80%<br />consisted of unchanged eprosartan.<br />The volume of distribution of eprosartan is about 13 litres. Total plasma clearance is about 130<br />ml/min. Biliary and renal excretion contribute to the elimination of eprosartan.<br />Both AUC and Cmax values of eprosartan are higher in elderly patients (on average,<br />approximately twice as high), but the dose does not have to be adjusted on this basis.<br />In patients with impaired renal function, the AUC values (but not the Cmax values) of eprosartan<br />(single 100 mg dose) are on average approximately 40% higher.<br />Compared with subjects with normal renal function, the mean AUC and Cmax values in patients<br />with moderately impaired renal function (creatinine clearance 30-59 ml/min) are approximately<br />30% higher, and in patients with severely impaired renal function (creatinine clearance 5-29<br />ml/min) are approximately 50% higher and in dialysis patients approximately 60% higher.<br />There are no differences in the pharmacokinetics of eprosartan between males and females.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General toxicology<br />Oral doses of eprosartan up to 1,000 mg/kg/daily for a maximum of 6 months in rats and for a<br />maximum of 1 year in dogs caused no significant drug-related toxicity at all.<br />Reproductive and developmental toxicity<br />In pregnant rabbits, eprosartan at 10 mg/kg/daily showed maternal and foetal toxicity only<br />during the last part of pregnancy. At 3 mg/kg/daily, maternal toxicity was observed, but no<br />foetal toxicity.<br />Genotoxicity<br />In a series of in vitro and in vivo studies, no genotoxicity was observed.<br />Carcinogenicity<br />In rats and mice that were given up to 600 and 2,000 mg/kg/daily respectively for 2 years, no<br />carcinogenicity was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core<br />600 mg tablet:<br />lactose monohydrate, microcrystalline cellulose, pregelatinised starch, crospovidone<br />magnesium stearate and purified water<br />Tablet coating<br />600 mg tablet:<br />Hypromellose (E464), macrogol 400, polysorbate 80 (E433), titanium dioxide (E171).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Teveten 600: 3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25 &deg;C.<br />Store in the original container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teveten 600:<br />White PVC/PVDC/Al blister: 14, 28 or 56 tablets in a blister pack.<br />White PVC/PCTFE/Al blister: 14, 28 or 56tablets in a blister pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Healthcare Products B.V.,
The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>